Leukemia and Lymphoma

Real-World Data Shows Higher Incidence of Neutropenia With Venetoclax, Obinutuzumab Combo in CLL

July 22nd 2021, 8:20pm

Article

Across 19 patients, 73% developed grade 3 or 4 neutropenia, significantly higher than the incidence observed in the phase 3 trial examining the combination for chronic lymphocytic leukemia (CLL).

Therapy Can Prevent Infections in Immunocompromised Patients With Leukemia

July 16th 2021, 5:00pm

Article

A new treatment using human immune cells can prevent infections in patients with leukemia who have a weakened immune system due to treatment for their disease.

MRD-Guided Decisions May Aid Postremission Treatment Choices in Type of AML

July 13th 2021, 6:20pm

Article

Based on subgroup analyses of over 500 younger patients with intermediate-risk disease, the researchers say measurable residual disease (MRD)-guided decisions may help achieve better outcomes postremission.

Genomic Landscapes and Outcomes in Elderly Patients With AML

July 9th 2021, 1:30pm

Article

Posters presented at the European Hematology Association 2021 Virtual Congress evaluated acute myeloid leukemia (AML) in elderly patients.

Researchers Offer Road Map for CAR T-Cell Treatment for B-ALL

July 5th 2021, 5:00pm

Article

The researchers outlined patient selection for treatment, adverse event management, and future strategies for the treatment of these patients.

Real-world Data Show Patterns of Care Don’t Follow Recommendations in Mantle Cell Lymphoma

July 4th 2021, 2:00pm

Article

A retrospective analysis of real-world data found a discrepancy between actual care and the recommendations from clinical trials for patients with mantle cell lymphoma, resulting in outcomes that were worse than in trials.

Studies Offer Promising Data on CAR T-cell Therapy in B-ALL, Multiple Myeloma

July 2nd 2021, 6:26pm

Article

Two abstracts presented recently at the American Society of Clinical Oncology annual meeting offered promising data for 2 CAR T-cell therapies, one in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and one in R/R multiple myeloma.

NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia

June 28th 2021, 3:30pm

Article

The National Comprehensive Cancer Network (NCCN) has updated its guidelines for Waldenström macroglobulinemia to include zanubrutinib (Brukinsa) as a preferred regimen.

Using Social Media for Insight Into Patient Experience With ALL and Its Treatments

June 26th 2021, 7:30pm

Article

An analysis of social media posts provides insight into patient experiences of acute lymphoblastic leukemia (ALL) and the therapies that treat it.

Convalescent Plasma Treatment Increases Odds of COVID-19 Survival Among Patients With Hematologic Malignancies

June 25th 2021, 8:30pm

Article

The study included over 900 patients with hematologic cancers who were hospitalized with COVID-19, revealing that giving patients plasma from people who have recovered from the virus improved the rate of 30-day mortality.